Mackett M, Cox C, Pepper S D, Lees J F, Naylor B A, Wedderburn N, Arrand J R
Department of Molecular Biology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Withington, Manchester, England.
J Med Virol. 1996 Nov;50(3):263-71. doi: 10.1002/(SICI)1096-9071(199611)50:3<263::AID-JMV9>3.0.CO;2-7.
Epstein-Barr virus (EBV) is the cause of infectious mononucleosis and is associated with a variety of life-threatening diseases in humans. Therefore the development of an effective vaccine is an important objective. Many of the initial studies of vaccine efficacy analyse the ability of vaccine preparations to prevent the induction of lymphomas in cottontop tamarins by the B95-8 strain of EBV. We used a vaccinia virus recombinant expressing gp340, vMA1, tested previously in the cotton-top tamarin, to evaluate a common marmoset model in which the challenge virus, M81, resembles more closely the wild-type strains of EBV in the general population than does the standard B95-8 strain. We characterised the M81 strain of EBV with respect to the sequence of its gp340/220 gene and in regard to the presence of a region deleted in B95-8. Replication of the challenge virus in the group vaccinated with vMA1 was decreased when compared to control groups.
爱泼斯坦-巴尔病毒(EBV)是传染性单核细胞增多症的病因,与人类多种危及生命的疾病相关。因此,开发一种有效的疫苗是一个重要目标。许多疫苗效力的初步研究分析了疫苗制剂预防B95-8株EBV诱导棉顶狨猴淋巴瘤的能力。我们使用了一种表达gp340的痘苗病毒重组体vMA1,该重组体先前已在棉顶狨猴中进行过测试,以评估普通狨猴模型,在该模型中,攻击病毒M81在总体上比标准B95-8株更类似于EBV的野生型菌株。我们对EBV的M81株进行了gp340/220基因序列以及B95-8中缺失区域存在情况的表征。与对照组相比,接种vMA1的组中攻击病毒的复制减少。